Weight-Based Targets and a Daily Cap Limited Actual Cannabinoid Doses in the Autism Trial
The autism trial’s highest weight-based target was not the actual daily dose received by every participant. Weight categories and an absolute daily cap affected achieved exposure.
Both CBD and THC increased together
The active preparations used a 20:1 CBD-to-THC ratio and were titrated in paired increments. Targets differed for children weighing twenty to forty kilograms and participants above forty kilograms. An absolute maximum of 420 milligrams CBD and 21 milligrams THC per day applied.
A cap changes the milligram-per-kilogram comparison
For a heavier participant, reaching the absolute cap can mean a lower dose per kilogram than the nominal weight-based target. The paper noted this issue when reporting average exposure. A target stated in the methods should not be assigned automatically to every person in an outcome or adverse-event calculation.
The trial did not randomize dose independently
The study compared preparations with placebo, not every achieved dose against every other dose. Both cannabinoids changed together, so a dose-response association would not isolate CBD from THC. Titration and tolerability also influenced the regimen. Preserve the ratio, weight rule and cap when describing this clinical experiment; none supplies an individual dosing recommendation or proof that a higher achieved dose caused a greater behavioral benefit.
Related analysis: the study’s broader findings and limitations.
Research cited
Aran and colleagues (2021). Cannabinoid treatment for autism: a proof-of-concept randomized trial.
